Our History
Beginning with the acquisition of Dabur Pharma Limited by Fresenius Kabi Singapore Pte Limited (part of Fresenius Kabi Group) in 2008, the Company has come a long way and established itself as a leading player in the field of generic oncology products and thrives for research and development and manufacture of life-saving medicines for cancer therapy.
2008
Fresenius Kabi Singapore Pte Limited
(a part of Fresenius Kabi Group) acquired Dabur Pharma Limited from its
Promoters, Burman Families.
2009
Name of the Company changed as
Fresenius Kabi Oncology Limited, marking the complete integration of the acquired
Company with Fresenius Kabi.
2010
Opening of newly developed Research
& Development Center and Corporate Office at Gurgaon, Haryana.
2011
Facility upgradation for APIs and
Intermediates - 10DAB, MTSC-9 and MS block for Irinotecan (Int) start-up at
Production Unit in Kalyani, West Bengal.
2012
Second filling line for the sterile injections added
as part of capacity enhancement at the Production Unit
in Kishanpura, Nalagarh, Himachal Pradesh.
2016
Microbiological testing laboratory revamped as part
of continuous quality improvement at Production Unit in Kishanpura, Nalagarh, Himachal Pradesh.
2019
Start-up
of New Excipient block for Cremophor and Polysorbate manufacturing at
Production Unit in Kalyani, West Bengal.
Consolidation of Finished
Dosage Formulations manufacturing operations from multiple Units in Baddi into the Unit located at Kishanpura in Nalagarh, Himachal Pradesh.
Project approved for addition of capability in Kishanpura, Nalagarh
Unit for Anti-infective and general products (Injection) Portfolio besides the
existing facility for manufacture of the Oncology products.
